We All Own This!

I have the good fortune to be on the boards of a number of foundations that support cancer research. At a recent meeting of one of these organizations, a lay board member asked if we thought we were making an impact with our grant program. It caused me to pause and think. How do you measure impact? How do you quantify what factors led to a breakthrough discovery for cancer treatment or a new strategy to prevent disease in the first place?

Every breakthrough represents the apex of a virtual pyramid of building blocks: experiments that worked and those that didn’t; new bits of knowledge leading to even more findings. Each piece of the puzzle is often funded by a different source. Any accomplished scientist’s funding portfolio will be diverse. Funding might come from various agencies within the government, private foundations, industrial sources, or even philanthropy. Can you attribute an accomplishment to a particular grant? That would be hard to do. And what about the dedicated graduate and postgraduate students, usually funded by training grants, who did the “hands on” work at the bench? That funding is pretty important too.

Furthermore, for cancer treatment, a new discovery isn’t really a breakthrough until it has meaning for patients and actually works. That means that a company and investors took a chance on the new asset and supported the clinical trials. So when you look in the rearview mirror at improved treatment, you have to credit the scientists and their brilliant ideas, the research team, all the funding agencies and the reviewers who saw something important that needed to be supported, the patients and families who participated in clinical research, and the investment in sweat or equity of all participants throughout the process.

When it comes to prevention, the story gets more complicated. Prevention doesn’t work if public health agencies don’t promote a prevention practice, if doctors in the trenches don’t discuss it with their patients, and if patients or young patients’ parents don’t put health first in their families. Disseminating and implementing any new strategy for prevention takes a virtual village, and seeing the effects may take a generation.

We are enjoying a good time in oncology. Death rates in the most common cancers are decreasing every year. New drugs are being developed at an unprecedented rate. We are already seeing the fruits of prevention in diseases like lung and colon cancer and are beginning to see declines in viral-related malignancies, such as cervical cancer and hepatocellular carcinoma, due to use of vaccines or antiviral drugs.

Of course, there is still much to be done, and we can’t rest or lower our vigilance. For instance, some diseases, such as pancreatic cancer, are growing in incidence, and we are seeing disturbing increases in colorectal cancer in younger adults. It seems that we will always have more work to do.

When we consider who should get credit for good outcomes in oncology, I agree there are clear leaders in science funded by many sources, who definitely deserve accolades. But when we look at the big picture, I think we all had some role and we all deserve some applause. Take a bow!

WHAT DO YOU THINK? To submit a Letter to the Editor, go to JNCCN@nccn.org or log into www.editorialmanager.com/JNCCN.


Margaret Tempero, MD, is a Professor of Medicine and Director of the UCSF Pancreas Center and editor-in-chief of JNCCN. Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer Cancer Foundation Board. She codirected the AACR/ASCO Methods in Clinical Cancer Research and taught this course and similar courses in Europe and Australia. She was founding Chair of the NCI Clinical Oncology Study Section and served as a member and Chair of the NCI Board of Scientific Counselors Subcommittee A. She is a member of the Scientific Steering Committee and Chair of the Clinical and Translational Study Section for the Cancer Prevention & Research Institute of Texas. She is or has been on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board, and the EORTC. She served as a member of the Oncology Drug Advisory Committee for the FDA. She has served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center. She is Chief Emeritus of the Division of Medical Oncology at UCSF. She served as the founding Deputy Director and was later Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center.

If the inline PDF is not rendering correctly, you can download the PDF file here.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 671 671 7
PDF Downloads 86 86 5
EPUB Downloads 0 0 0